Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Interest Income Expense
Aquestive Therapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Interest Income Expense
-$5.7m
|
CAGR 3-Years
30%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Interest Income Expense
$212m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Interest Income Expense
-$676m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Interest Income Expense
$1.5B
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Interest Income Expense
-$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-13%
|
|
Eli Lilly and Co
NYSE:LLY
|
Interest Income Expense
-$368m
|
CAGR 3-Years
-133%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-30%
|
See Also
What is Aquestive Therapeutics Inc's Interest Income Expense?
Interest Income Expense
-5.7m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Interest Income Expense amounts to -5.7m USD.
What is Aquestive Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
15%
The average annual Interest Income Expense growth rates for Aquestive Therapeutics Inc have been 30% over the past three years , 15% over the past five years .